Alternative investment strategies
Specialist advisory for life sciences mandates requiring institutional-grade documentation, stakeholder alignment, and disciplined execution from mandate design through close.
All industries
Industry advisory
Life Sciences
Financing innovation across biotech, pharma, and medtech
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Discuss your sector mandate with our team.Overview
Financing innovation across biotech, pharma, and medtech
We support life sciences companies and investors with alternative investment vehicles, clinical-stage risk assessment, and capital strategies for R&D-intensive growth.
US life sciences carry regulatory approval risk unlike any other sector, with value concentrated in intellectual property and clinical milestones. Financing is staged against those milestones rather than against operating cash flow.
Financing innovation across biotech, pharma, and medtech
- 4
Advisory pillars
Capital, risk, funds, and credit enhancement
- EMEA
Regulatory depth
Local frameworks across EMEA markets
- 360°
Mandate coverage
Strategy to execution in life sciences
- 26
Sector breadth
Cross-industry insight applied to your mandate
Sector perspective
US capital meets life sciences opportunity abroad
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Key challenges
Financing innovation across biotech, pharma, and medtech
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Structuring capital for life sciences assets amid evolving regulation and market volatility
Aligning innovation funding, IP ownership, and regulatory approval timelines with long-dated capital structures
Balancing long-dated life sciences cash flows with short-term liquidity and covenant expectations
Bridging clinical, regulatory, and technology-obsolescence risk with staged capital and milestone financing
Highlights
Financing innovation across biotech, pharma, and medtech
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Investment due diligence
Integrated risk frameworks covering political, regulatory, operational, and financial exposure — tailored to how life sciences assets perform across jurisdictions and market cycles.
US investor access
Direct connectivity for US institutional investors, family offices, and development finance institutions to well-structured life sciences opportunities across Europe, the Middle East and Africa.
Multi-jurisdictional execution
End-to-end support for multi-jurisdictional life sciences programs — from feasibility and due diligence through capital mobilization, monitoring, and portfolio reporting.
Expertise
Financing innovation across biotech, pharma, and medtech
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Advisory frameworks aligned with the regulatory and institutional standards of each destination market.
Our approach
We support life sciences companies and investors with alternative investment vehicles, clinical-stage risk assessment, and capital strategies for R&D-intensive growth. Our life sciences practice centers on milestone-based institutional capital advisory — translating sector complexity into bankable mandates, confident board decisions, and repeatable execution for US investors across Europe, the Middle East and Africa.
“Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.”
Mandate execution
From assessment to capital mobilization
Our advisory team structures life sciences mandates for US investors with the discipline institutional investors and development finance partners require.
Our process
A disciplined approach to capital advisory
We integrate financial expertise, policy insight, and strategic advisory capabilities to help clients structure bankable projects, mitigate risk, and mobilize capital with confidence.
Start a sector conversation
Tell us about your capital requirement, risk profile, or structuring objective.
Email us directly
[email protected]Assess
Diagnose life sciences capital requirements, stakeholder dynamics, and regulatory milestones, IP, and commercialization paths before structuring.
Assess 01
Structure
Design bankable milestone tranches and institutional co-investment aligned with life sciences cash flows and covenant standards.
Structure 02
Mobilize
Connect US institutional, development finance, and private capital with EMEA counterparties; coordinate due diligence and term sheet negotiation.
Mobilize 03
Monitor
Establish reporting cadences and oversight for regulatory, clinical, and commercialization milestones so life sciences investments remain transparent to financiers.
Monitor 04
Advisory frameworks aligned with the regulatory and institutional standards of each destination market.
Latest insights
Financing innovation across biotech, pharma, and medtech
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Outcomes
Outcomes
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Milestone-based and institutional capital structures matched to R&D and commercialization phases
Regulatory, IP, and technology risk diligence structured for staged investment decisions
Phased capital release tied to regulatory, clinical, or commercialization milestones
Milestone, clinical, and impact reporting suitable for institutional and DFI oversight
Related industries
All industries
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Sector mandate
Discuss your sector requirement
Capital structuring for biotech, pharmaceutical manufacturing, and the research base behind them.
Headquarters
Consultinghouse
Discuss your capital or investment mandate
United States · Munich
Industry advisory
Advisory frameworks aligned with the regulatory and institutional standards of each destination market.
Start a sector conversation
Tell us about your capital requirement, risk profile, or structuring objective.
Capital · ImpactUS capital · Cross-border mandates
Explore expertise